2026

Hepatic zonation determines tumorigenic potential of mutant β-catenin

Nature. doi: 10.1038/s41586-025-09733-1

Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling

Nature Genetics. doi: 10.1038/s41588-025-02496-5

Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models

Nature Reviews Gastroenterology & Hepatology. doi: 10.1038/s41575-025-01162-9

Understanding liver and digestive diseases: a paved road to improve diagnosis, management, and treatment 

Exploration of Digestive Diseases. doi: 10.37349/edd.2026.1005110

Improving surgical treatments for hepatocellular carcinoma

Nature Reviews Gastroenterology and Hepatology. doi: 10.1038/s41575-025-01143-y

Nrf2-mediated metabolic reprogramming drives regulatory T cell accumulation in hepatocellular carcinoma

Nature Communications. doi: 10.1038/s41467-026-73485-3

Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma

Journal of Hepatology. doi: 10.1016/j.jhep.2025.08.042

Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling

Nature Genetics. doi: 10.1038/s41588-025-02496-5

Activated ATF6α is a hepatic tumour driver restricting immunosurveillance

Nature. doi: 10.1038/s41586-025-10036-8

2025

Modeling the response to interleukin-21 to inform natural killer cell immunotherapy

Immunology & Cell Biology. doi: 10.1111/imcb.12848

Human-correlated genetic models identify precision therapy for liver cancer

Nature. doi: 10.1038/s41586-025-08585-z

A precision image-guided model of stereotactic ablative radiotherapy for hepatocellular carcinoma

Disease Models & Mechanisms. doi: 10.1242/dmm.052301

Abstract B135: Activity of Tegavivint in Hepatocellular Carcinoma with Aberrant Wnt/β-catenin Signaling and Evaluation of Biomarker Response

Molecular Cancer Therapeutics. 

PixlMap: A generalisable pixel classifier for cellular phenotyping in multiplex immunofluorescence images

PLoS One. doi: 10.1371/journal.pone.0317865

Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

Journal of Hepatology. doi: 10.1016/j.jhep.2024.12.016

Fine needle aspirates characterise the hepatocellular carcinoma immune niche to predict immune checkpoint inhibitor outcome 

JHEP Reports. doi: 10.1016/j.jhepr.2025.101637

Loss of p62 Binding Allows TIF-IA Accumulation in Senescence, Which Promotes Phenotypic Changes to Nucleoli and the Senescence Associated Secretory Phenotype

Aging Cell. doi: 10.1111/acel.70334

Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma

bioRxiv preprint. doi: 10.1101/2025.07.08.663653

Spatial lipidomics reveals sphingolipid metabolism as anti-fibrotic target in the liver

Metabolism. doi: 10.1016/j.metabol.2025.156237

Pharmacological manipulation of liver fibrosis progression using novel HDAC6 inhibitors

The FEBS Journal. doi: 10.1111/febs.70062

Precision-cut tumor slices for modeling hepatocellular carcinoma enable at-scale drug screening

Hepatology Communications. doi: 10.1097/HC9.0000000000000706

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS–chemokine–myeloid axis

bioRxiv preprint. doi: 10.1101/2025.05.06.652454

Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma

Journal of Hepatology. doi: 10.1016/j.jhep.2025.08.042

Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma

Journal of Hepatology. doi: 10.1016/j.jhep.2025.07.033

Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma

ESMO Open. doi: 10.1016/j.esmoop.2025.105065

British Society of Gastroenterology hepatocellular carcinoma guideline review: impact on the frontline

Hepatology Guideline review. doi: 10.1136/flgastro-2024-102927

CIA: unveiling cellular identities with cluster- independent annotation in single-cell RNA sequencing data for comprehensive cell type characterization and exploration

BMC Bioinformatics. doi: 10.1186/s12859-025-06320-z

Secretory IgA amplification during immune checkpoint blockade enhances the control of tumor growth by enterotropic T cells

Science Advances. doi: 10.1126/sciadv.aeb5308

Dual Activation-Induced Marker Combinations Efficiently Identify and Discern Antigen-Specific and Bystander-Activated Human CD4+ T Cells

European Journal of Immunology. doi: 10.1002/eji.202451404

Prolonged persistence of mutagenic DNA lesions in somatic cells

Nature. doi: 10.1038/s41586-024-08423-8

E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma

Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-25-0725

Hepatocellular carcinoma: Epidemiology, diagnosis and treatment

JHEP Reports. doi: 10.1016/j.jhepr.2025.101571

Artificial intelligence predicts outcome-related molecular profiles and vascular invasion in hepatocellular carcinoma

JHEP Reports. doi: 10.1016/j.jhepr.2025.101592

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology. doi: 10.1002/1878-0261.70168

Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Liver Cancer. doi: 10.1159/000549565

2024

MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges

Cancers (Basel). doi: 10.3390/cancers16020259

Harnessing natural killer cell effector function against cancer

Immunotherapy Advances. doi: 10.1093/immadv/ltad031

The nuclear export protein XPO1 provides a peptide ligand for natural killer cells

Science Advances. doi: 10.1126/sciadv.ado6566

Multimodal decoding of human liver regeneration

Nature. doi: 10.1038/s41586-024-07376-2

Immunotherapy for hepatocellular carcinoma

JHEP Reports. doi: 10.1016/j.jhepr.2024.101130

UCHL1-dependent control of hypoxia-inducible factor transcriptional activity during liver fibrosis

Bioscience Reports. doi: 10.1042/BSR20232147

Hepatocellular senescence induces multi-organ senescence and dysfunction via TGFβ

Nature Cell Biology. doi: 10.1038/s41556-024-01543-3

T-Cell Immune Responses to SARS-CoV-2 Infection and Vaccination

Vaccines (Basel). doi: 10.3390/vaccines12101126

BACH2 regulates diversification of regulatory and proinflammatory chromatin states in TH17 cells

Nature Immunology. doi: 10.1038/s41590-024-01901-1

Tracking the immune response profiles elicited by the BNT162b2 vaccine in COVID-19 unexperienced and experienced individuals

Clinical Immunology. doi: 10.1016/j.clim.2024.110164

Protocol for the detection of defined T cell clones in a heterogeneous cell population

STAR Protocols. doi: 10.1016/j.xpro.2023.102787

A Glance at the Innate Immune Response Elicited by Infection and Vaccination

Antibodies (Basel). doi: 10.3390/antib13010013

Novel immunotherapeutics against LGR5 to target multiple cancer types 

EMBO Molecular Medicine. doi: 10.1038/s44321-024-00121-2

Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review

JAMA Oncology. doi: 10.1001/jamaoncol.2023.2677

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma

Nature Reviews Clinical Oncology. doi: 10.1038/s41571-024-00868-0

Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy

Gastro Hep Advances. doi: 10.1016/j.gastha.2024.01.009

Two decades of advances in clinical oncology - lessons learned and future directions

Nature Reviews Clinical Oncology. doi: 10.1038/s41571-024-00945-4

Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC

JHEP Reports. doi: 10.1016/j.jhepr.2024.101212

Hepatocellular carcinoma hosts cholinergic neural cells and tumoral hepatocytes harboring targetable muscarinic receptors

JHEP Reports. doi: 10.1016/j.jhepr.2024.101245

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma

JHEP Reports. doi: 10.1016/j.jhepr.2024.101246

2023

Operando NMR metabolomics of a microfluidic cell culture

Journal of Magnetic Resonance. doi: 10.1016/j.jmr.2023.107405

The senescent secretome drives PLVAP expression in cultured human hepatic endothelial cells to promote monocyte transmigration

iScience. doi: 10.1016/j.isci.2023.107966

What is the current status of multicancer early detection tests and upper gastrointestinal cancer? 

The Lancet Gastroenterology & Hepatology. doi: 10.1016/S2468-1253(23)00249-2

2022

Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification

Gut. doi: 10.1136/gutjnl-2021-325918

2021

Convergent somatic mutations in metabolism genes in chronic liver disease

Nature. doi: 10.1038/s41586-021-03974-6

The human liver microenvironment shapes the homing and function of CD4⁺ T-cell populations

Gut. doi: 10.1136/gutjnl-2020-323771

Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma

Journal of Hepatology. doi: 10.1016/j.jhep.2021.05.015

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Nature. doi: 10.1038/s41586-021-03362-0

Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores

Journal of Hepatology. doi: 10.1016/j.jhep.2020.11.024

TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms

Gut. doi: 10.1136/gutjnl-2019-319227

2020

Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications

Journal of Hepatology. doi: 10.1016/j.jhep.2020.03.025

Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma

Journal of Hepatology. doi: 10.1016/j.jhep.2020.03.008

Liver-resident CD8+ T cells: Learning lessons from the local experts

Journal of Hepatology. doi: 10.1016/j.jhep.2020.02.001

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma

Journal of Hepatology. doi: 10.1002/hep.30811

2019

The landscape of gene mutations in cirrhosis and hepatocellular carcinoma

Journal of Hepatology. doi: 10.1016/j.jhep.2020.01.019

Somatic mutations and clonal dynamics in healthy and cirrhotic human liver

Nature. doi: 10.1038/s41586-019-1670-9

Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival

Journal of Hepatology. doi: 10.1016/j.jhep.2019.01.028

Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage

Gut. doi: 10.1136/gutjnl-2017-314107